Related Experiment Videos
Adverse events in methotrexate-treated rheumatoid arthritis patients
D M Sandoval1, G S Alarcón, S L Morgan
1Department of Medicine, University of Alabama at Birmingham, USA.
Abstract:
Methotrexate (MTX) is an antifolate that has been in use for the treatment of rheumatoid arthritis (RA) since the early 1980s. Its efficacy has been clearly documented [1-4] and its administration early in the course of the disease is now generally accepted [5]. Side-effects from low weekly pulse MTX have been reported [1-6] and it was our initial experience that toxicity, rather than lack of efficacy, was the major factor limiting its clinical use [7]. However, when compared with other disease-modifying antirheumatic drugs, its toxicity appears to be comparable to that of antimalarials [8, 9]. The purpose of this paper is to discuss the possible mechanisms responsible for toxicity due to MTX used at low weekly pulse doses for the treatment of RA, as well as the different toxic manifestations reported in the literature.
Insights
Methotrexate (MTX) effectively treats rheumatoid arthritis (RA), but its low-dose weekly use can cause side effects. This review explores MTX toxicity mechanisms and manifestations in RA patients.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Methotrexate (MTX) has been a cornerstone treatment for rheumatoid arthritis (RA) since the early 1980s.
- Early administration of MTX in RA is widely accepted due to its proven efficacy.
- While effective, MTX toxicity can limit its clinical application.
Purpose of the Study:
- To elucidate the mechanisms underlying toxicity associated with low-dose weekly methotrexate (MTX) in rheumatoid arthritis (RA) treatment.
- To review the spectrum of toxic manifestations reported with MTX in RA patients.
Main Methods:
- Literature review of studies on methotrexate (MTX) for rheumatoid arthritis (RA).
- Analysis of reported side effects and toxicity mechanisms.
- Comparison of MTX toxicity with other disease-modifying antirheumatic drugs (DMARDs).
Main Results:
- Methotrexate (MTX) efficacy in rheumatoid arthritis (RA) is well-established.
- Toxicity, not lack of efficacy, is often the primary limitation for MTX use.
- MTX toxicity is comparable to that of antimalarials when used for RA.
Conclusions:
- Understanding MTX toxicity mechanisms is crucial for optimizing RA treatment.
- Identifying and managing MTX side effects can improve patient outcomes.
- Methotrexate remains a valuable therapeutic option for RA despite potential toxicities.